Navigation Links
Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer
Date:1/14/2009

ne is the most common organ to be affected by metastatic cancer (Ref. 1). Approximately 1.5 million cancer patients suffer from bone metastases worldwide and there are some 300,000 new cases each year. Importantly, metastases may stay confined to the skeleton with subsequent morbidity and eventual death almost entirely due to skeletal complications and their treatment.

Some 80% of bone metastases are due to prostate and breast carcinomas. For these high incidence cancers, 65-75% patients with advanced disease will have bone metastases (Ref. 2). They may suffer multiple skeletal complications over several years because the clinical course of metastatic bone disease is relatively long. The effects are often debilitating (intractable bone pain, fractures, hypercalcaemia, and spinal cord compression) and profoundly impair a patient's quality of life.

Bone metastases also occur frequently in patients with lung, kidney and thyroid cancers - respectively in 30-40%, 20-25% and 60% of patients with advanced disease.

Current treatments for skeletal metastases are largely palliative. They include opioid analgesics, external beam radiotherapy, beta-emitting radionuclides and bisphosphonates.

References

1. Coleman, R.E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12:6243s-6249s. Review

2. Rubens, R.D, and Coleman, R.E. Bone Metastases. In: Abaloff, M.D., Armitage, J.O., Lichter, A.S. and Niederhuber, J.E. Clinical Oncology 1995: 643-665

Forward-looking Statement

This news release contains forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on results of operations and the financial condition of Algeta. There are a number of factors that could cause ac
'/>"/>

SOURCE Algeta
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
2. MicroPhage Successfully Completes Beta Trial for Rapid MRSA Test
3. Jazz Pharmaceuticals, Inc. Completes Enrollment in Second of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
4. Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment
5. Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
6. Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma
7. Essentialis Completes Patient Enrollment in Phase 2 Trial of DDCR for Treatment of Dyslipidemia
8. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
9. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
10. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
11. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... SALT LAKE CITY , Aug. 28, 2014 /PRNewswire-iReach/ ... in 2000 by service academy graduates, has published a ... its concentrated, three-day Leadership Excellence Course . In ... the  Leadership Excellence Course to Albuquerque , ... Tucson . Photo - http://photos.prnewswire.com/prnh/20140828/140814 ...
(Date:8/28/2014)... 28, 2014 The new ... Market (products, applications, techniques, end users and Geography) ... Forecast, 2013 - 2020," indicates that the global ... 2020 registering a CAGR of 9.8% from 2014 ... and cost effectiveness over alternative diagnostic techniques are ...
(Date:8/28/2014)... Aug. 28, 2014   Venaxis, Inc.  (Nasdaq:  APPY), ... obtaining FDA clearance for and commercializing its CE Marked ... aiding in identifying children, adolescent, and young adult patients ... for appendicitis, today announced it will present at three ... Annual Global Investment Conference being held in ...
Breaking Medicine Technology:Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 2DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 3Venaxis to Present at September Investor Conferences 2Venaxis to Present at September Investor Conferences 3
... 2010 Kensey Nash Corporation (Nasdaq: KNSY ... in November.   Michael Celano, Kensey Nash,s ... the Oppenheimer 21st Annual Healthcare Conference at the Waldorf ... p.m. (ET).  To hear the live webcast of the ...
... (Nasdaq: SLTM ), a global leader in the ... ended September 30, 2010. Revenue for the third quarter was ... as compared to the third quarter 2009 revenue of $17.8 ... by a year-over-year 40% increase in sales of treatment tips ...
Cached Medicine Technology:Solta Medical Reports Third Quarter 2010 Results 2Solta Medical Reports Third Quarter 2010 Results 3Solta Medical Reports Third Quarter 2010 Results 4Solta Medical Reports Third Quarter 2010 Results 5Solta Medical Reports Third Quarter 2010 Results 6Solta Medical Reports Third Quarter 2010 Results 7Solta Medical Reports Third Quarter 2010 Results 8
(Date:8/28/2014)... Solid-head power toothbrushes retain less bacteria compared ... University of Texas Health Science Center at Houston ... study are published in the August issue of ... professor at the UTHealth School of Dentistry, Donna ... were lower in the solid-head toothbrush group than ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 ISI ... management solutions, will be sponsoring the 2014 Presidio ... annual event allows Presidio leadership to engage with ... year. Specifically, they will be rolling out objectives ... , While at the event, ISI will be ...
(Date:8/28/2014)... A candidate Ebola vaccine could be given to healthy ... early as September, as part of an series of ... disease that has killed more than 1,400 people in ... of this candidate vaccine, being co-developed by the US ... be accelerated with funding from an international consortium in ...
(Date:8/28/2014)... Initial human testing of an investigational vaccine to prevent ... National Institute of Allergy and Infectious Diseases (NIAID), part ... trial will begin initial human testing of a vaccine ... the experimental vaccine,s safety and ability to generate an ... place at the NIH Clinical Center in Bethesda, Maryland. ...
(Date:8/28/2014)... People aged 70 and over who identify themselves as ... where they perceive they have lower value than younger ... University of Kent, titled ,Being old and ill, across ... subjective health, used data from the European Social Survey. ... asked to self-rate their health., The researchers found that ...
Breaking Medicine News(10 mins):Health News:UTHealth researchers find up to 3,000 times the bacterial growth on hollow-head toothbrushes 2Health News:ISI Telemanagement Solutions, Inc. to Sponsor 2014 Presidio Exchange 2Health News:Ebola vaccine trials fast-tracked by international consortium 2Health News:Ebola vaccine trials fast-tracked by international consortium 3Health News:Ebola vaccine trials fast-tracked by international consortium 4Health News:NIH to Launch human safety study of Ebola vaccine candidate 2Health News:NIH to Launch human safety study of Ebola vaccine candidate 3Health News:NIH to Launch human safety study of Ebola vaccine candidate 4Health News:NIH to Launch human safety study of Ebola vaccine candidate 5
... today announced their plans to expand their online video ... overwhelming success achieved by the website since its inception ... library has been visited by physicians from 64 different ... from repeat visits and the average length of stay ...
... Recent Developments at Major Patenting Authorities WorldwidePHILADELPHIA and LONDON, ... Thomson Reuters today released its 2009 Patent Focus ... Intellectual Asset Management magazine, and published in the ... , this report explores recent activities at each of ...
... SEATTLE, Feb. 17 Cell Therapeutics, Inc. (Nasdaq and ... a press release in Italy in response to information ... CTI,s business operations and financial condition, which was also ... February 17, 2009, the Borsa Italiana has confirmed that ...
... 17 The civil rights movement gained a ... of Representatives voted Feb. 17 to recognize the ... by American Life League Associate group North Dakota ... of The Personhood of Children Act (House Resolution ...
... Consumers who purchased raw milk from the Swiss Villa ... after Feb. 9 are advised to discard it immediately ... Secretary Dennis Wolff said today. Raw milk has not ... a result of the potential contamination, but if people ...
... Shenghuo,Pharmaceutical Holdings, Inc. (NYSE Alternext US: KUN) ("China ... 10, 2009, it received a,deficiency letter from the ... the,"Exchange") stating that the Company was not in ... standards due to the Company,s failure to,hold an ...
Cached Medicine News:Health News:Physicians online library is a worldwide hit 2Health News:Physicians online library is a worldwide hit 3Health News:Thomson Reuters Releases 2009 Patent Focus Report 2Health News:Cell Therapeutics to Resume Trading on MTA and NASDAQ 2Health News:North Dakota Personhood Bill Passes State House 51-41 2Health News:Consumer Advisory: Agriculture Department Warns of Tainted Raw Milk Sold By Dauphin County Dairy 2Health News:China Shenghuo Receives Notice from NYSE Alternext US Regarding Listing Standards 2Health News:China Shenghuo Receives Notice from NYSE Alternext US Regarding Listing Standards 3
... ROM Elbow Orthosis features aluminum cuffs that ... arm. To ensure proper joint alignment, unique ... and distal adjustments to cuff position. Cuffs ... is necessary for use with contractures.,The hinge ...
... Brace is designed to handle post-op elbow ... The Bledsoe Extender Arm Brace should be ... of the elbow is desired. In most ... be formed, fitted and adjusted in 5 ...
... This controlled stretch ankle support helps reduce ... of motion. It is easy to apply ... its slim design fits easily into shoes. ... the ankle, and provide side-to-side support and stability. ...
... ankle support provides excellent com-pression and ... motion. The anatomically sculpted visco-elastic ... weakened or injured soft tissues under ... to apply - slips on like ...
Medicine Products: